E
Edgewise Therapeutics, Inc. (EWTX)
NMS – Real Time Price. Currency in USD
33.64
-0.37 (-1.09%)
Market open: May 13, 2026, 1:48 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
33.64
-0.37 (-1.09%)
Market open: May 13, 2026, 1:48 PM EDT
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Name | Position |
|---|---|
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer & Director |
| Dr. Badreddin Edris Ph.D. | Co-Founder & Independent Director |
| Dr. Behrad Derakhshan Ph.D. | Chief Operating Officer |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer |
| Dr. Kevin Koch Ph.D. | President, CEO & Director |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Chairman |
| Mr. John R. Moore J.D. | General Counsel |
| Mr. Michael P. Nofi | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | S-8 | tm2613274d1_s8.htm |
| 2026-05-07 | 10-Q | ewtx-20260331x10q.htm |
| 2026-04-23 | DEFA14A | ewtx-20260423xdefa14a.htm |
| 2026-02-26 | 8-K | tm266859d1_8k.htm |
| 2025-11-20 | 8-K | tm2531112d1_8k.htm |
| 2025-11-10 | 8-K | tm2530663d1_8k.htm |
| 2025-11-06 | 8-K | tm2529979d1_8k.htm |
| 2025-08-07 | 8-K | tm2522645d1_8k.htm |
| 2025-06-26 | 8-K | tm2519221d1_8k.htm |
| 2025-05-08 | 8-K | tm2513845d1_8k.htm |